Why the study?
Does sotatercept reduce the risk of death, lung transplantation, or hospitalization in high-risk adults with pulmonary arterial hypertension on maximum tolerated background therapy?
Does sotatercept reduce the risk of death, lung transplantation, or hospitalization in high-risk adults with pulmonary arterial hypertension on maximum tolerated background therapy?
Sotatercept reduces the composite risk of death, lung transplantation, or worsening PAH hospitalization in high-risk patients already on maximal background therapy.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Pooled analyses across trials further suggest that sotatercept may have a meaningful impact on mortality in patients with PAH.”
Supports adding sotatercept in high-risk PAH on maximal therapy; challenges prior low-certainty evidence against benefit.
Among high-risk adults with pulmonary arterial hypertension who were receiving the maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening pulmonary arterial hypertension than placebo. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; ZENITH ClinicalTrials.gov number, NCT04896008.).
No takes yet. Share an insight, caveat, or question.
Humbert et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: